SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-006325
Filing Date
2022-02-10
Accepted
2022-02-10 12:34:38
Documents
14
Period of Report
2022-02-10
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea155351-8k_inmed.htm   iXBRL 8-K 26718
2 NEWS RELEASE, DATED FEBRUARY 10, 2022 ea155351ex99-1_inmed.htm EX-99.1 8579
3 GRAPHIC ex99-1_001.jpg GRAPHIC 5348
  Complete submission text file 0001213900-22-006325.txt   220550

Data Files

Seq Description Document Type Size
4 XBRL LABEL FILE inm-20220210_lab.xml EX-101.LAB 34476
5 XBRL SCHEMA FILE inm-20220210.xsd EX-101.SCH 3039
6 XBRL PRESENTATION FILE inm-20220210_pre.xml EX-101.PRE 22600
8 EXTRACTED XBRL INSTANCE DOCUMENT ea155351-8k_inmed_htm.xml XML 3750
Mailing Address SUITE 310, 815 W. HASTINGS STREET VANCOUVER A1 V6C 1B4
Business Address SUITE 310, 815 W. HASTINGS STREET VANCOUVER A1 V6C 1B4 (604) 669-7207
InMed Pharmaceuticals Inc. (Filer) CIK: 0001728328 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-39685 | Film No.: 22612553
SIC: 2834 Pharmaceutical Preparations